|
1 Gordon PM, Diffey BL, Mathews JN, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J AM Acad Dermatol. 1999 Nov; 41 (5 Pt 1).728-32.
|
|
2 Morison, WL. Phototherapy and Photochemotherapy. Adv Dermatol. 1992; 7:260.
|
|
3 Oxsoralen-Ultra® capsules Full Prescribing Information.
|
|
4 Morison, Dr. Warwick L., PUVA Therapy Guide. www.lightandlaser.com, 2000.
|
|
5 Koo, John MD and Mark Lebwohl, MD. Duration of remission of psoriasis therapies. J Am Acad Dermatol. 1999; 41: 51-59.
|
|
6 Morison, WL. Phototherapy and Photochemotherapy of Skin Disease. 2nd ed. New York, NY: Raven Press; 1991:69.
|
|
7 Shelk, JL. Phototherapy: a nursing overview. Dermatology Nursing. 1991;3(6):401-407.
|
|
8 Morison, WL. Phototherapy and Photochemotherapy of Skin Disease. 2nd ed. New York, NY: Raven Press; 1991:200.
|
|
9 McClelland, Patricia B., RN. PUVA Instructional Manual. A Training Guide for Professionals Who Administer PUVA Therapy. Valeant Pharmaceuticals International 1997.
|
|
10 Medicare Reimbursements for Phototherapy to Increase. Psoriasis Forum. National Psoriasis Foundation. Winter 2001, 7:2.
|
|
11 Morison, WL. Phototherapy and Photochemotherapy of Skin Disease. 2nd ed. New York, NY: Raven Press; 1991:68.
|
|
12 Drake, LA, et al. Guidelines of care for psoriasis. J Am Acad Dermatol. 1993; 28:632-637.
|
|
13 Morison, WL. Phototherapy and Photochemotherapy, Adv Dermatol. 1992;7:262.
|
|
14 Data on file. Valeant Pharmacetuticals International
|
OXSORALEN-ULTRA® CAPSULES
(Methoxsalen Capsules, USP, 10mg)
Rx only
CAUTION: METHOXSALEN IS A POTENT DRUG. READ ENTIRE BROCHURE PRIOR TO PRESCRIBING OR DISPENSING THIS MEDICATION.
Methoxsalen with UV radiation should be used only by physicians who have special competence in the diagnosis and treatment of psoriasis and who have special training and experience in photochemotherapy. The use of Psoralen and ultraviolet radiation therapy should be under constant supervision of such a physician. For the treatment of patients with psoriasis, photochemotherapy should be restricted to patients with severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis is certain. Because of the possibilities of ocular damage, aging of the skin, and skin cancer (including melanoma), the patient should be fully informed by the physician of the risks inherent in this therapy. |
CAUTION: Oxsoralen-Ultra® (Methoxsalen Soft Gelatin Capsules) should not be used interchangeably with regular Oxsoralen® or 8-MOP® (Methoxsalen Hard Gelatin Capsules). This new dosage form of methoxsalen exhibits significantly greater bioavailability and earlier photosensitization onset time than previous methoxsalen dosage forms. Patients should be treated in accordance with the dosimetry specifically recommended for this product. The minimum phototoxic dose (MPD) and phototoxic peak time after drug administration prior to onset of photochemotherapy with this dosage form should be determined. |
|
